Brief: Acelyrin And Alumis Reaffirm Strategic And Financial Rationale Of Proposed Merger
04/03/2025 14:06
March 4 (Reuters) - Alumis Inc ALMS.O: ACELYRIN AND ALUMIS REAFFIRM STRATEGIC AND FINANCIAL RATIONALE OF PROPOSED MERGER Source text: ID:nGNXc7ThR1 Further company coverage: ALMS.O (Reuters.Briefs@thomsonreuters.com)
Recent news on Alumis
See all newsBrief: Alumis Says Envudeucitinib Improves Psoriasis Symptoms in Phase 3 Data
U.S. RESEARCH ROUNDUP-Adobe, Dell Technologies, Zscaler
Alumis set for worst day after lupus drug misses main goal in mid-stage trial
Alumis eyes late-stage lupus study despite trial miss (updated)
Alumis tumbles after lupus drug misses main goal in mid-stage trial